A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder

Part of paid clinical trials in Los Alamitos, California.

Sponsor
AbbVie
Study ID
NCT07071532
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • ABBV-932 — DRUG
    Oral Capsule
  • Itraconazole — DRUG
    Oral Capsule

Study Details

This study will assess the adverse events and how oral ABBV-932 moves through the body when given with oral Itraconazole in adult participants with bipolar disorder.

Key Dates

First listed
Jul 17, 2025
Start date
Aug 20, 2026
Status verified
Sep 2026
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: ABBV-932 with Itraconazole
    Participants will receive ABBV-932 in Period 1 followed by Itraconalzole in combination with ABBV-932 in Period 2.

Primary Outcome Measure

Maximum Plasma Concentration (Cmax) of ABBV-932 and active metabolites DCAR and DDCAR [ Time Frame: Up to approximately 29 days ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
CenExel Collaborative Neuroscience Research /ID# 282784Los AlamitosCalifornia90720-
Acpru /Id# 276951GrayslakeIllinois60030-

Find similar trials in Los Alamitos, CA

Nationwide
Bipolar disorder trialsPsychiatry trialsMental health trialsBehavioral health trials
By condition
Bipolar disorder
By specialty
PsychiatryMental healthBehavioral health
By research site
CenExel Collaborative Neuroscience Research· Los Alamitos, CAAcpru· Grayslake, IL

Related Studies